Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Ugur Sahin (), Evelyna Derhovanessian, Matthias Miller, Björn-Philipp Kloke, Petra Simon, Martin Löwer, Valesca Bukur, Arbel D. Tadmor, Ulrich Luxemburger, Barbara Schrörs, Tana Omokoko, Mathias Vormehr, Christian Albrecht, Anna Paruzynski, Andreas N. Kuhn, Janina Buck, Sandra Heesch, Katharina H. Schreeb, Felicitas Müller, Inga Ortseifer, Isabel Vogler, Eva Godehardt, Sebastian Attig, Richard Rae, Andrea Breitkreuz, Claudia Tolliver, Martin Suchan, Goran Martic, Alexander Hohberger, Patrick Sorn, Jan Diekmann, Janko Ciesla, Olga Waksmann, Alexandra-Kemmer Brück, Meike Witt, Martina Zillgen, Andree Rothermel, Barbara Kasemann, David Langer, Stefanie Bolte, Mustafa Diken, Sebastian Kreiter, Romina Nemecek, Christoffer Gebhardt, Stephan Grabbe, Christoph Höller, Jochen Utikal, Christoph Huber, Carmen Loquai and Özlem Türeci
Additional contact information
Ugur Sahin: Biopharmaceutical New Technologies (BioNTech) Corporation
Evelyna Derhovanessian: Biopharmaceutical New Technologies (BioNTech) Corporation
Matthias Miller: Biopharmaceutical New Technologies (BioNTech) Corporation
Björn-Philipp Kloke: Biopharmaceutical New Technologies (BioNTech) Corporation
Petra Simon: Biopharmaceutical New Technologies (BioNTech) Corporation
Martin Löwer: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
Valesca Bukur: Biopharmaceutical New Technologies (BioNTech) Corporation
Arbel D. Tadmor: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
Ulrich Luxemburger: Biopharmaceutical New Technologies (BioNTech) Corporation
Barbara Schrörs: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
Tana Omokoko: Biopharmaceutical New Technologies (BioNTech) Corporation
Mathias Vormehr: Biopharmaceutical New Technologies (BioNTech) Corporation
Christian Albrecht: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
Anna Paruzynski: Biopharmaceutical New Technologies (BioNTech) Corporation
Andreas N. Kuhn: Biopharmaceutical New Technologies (BioNTech) Corporation
Janina Buck: Biopharmaceutical New Technologies (BioNTech) Corporation
Sandra Heesch: Biopharmaceutical New Technologies (BioNTech) Corporation
Katharina H. Schreeb: Biopharmaceutical New Technologies (BioNTech) Corporation
Felicitas Müller: Biopharmaceutical New Technologies (BioNTech) Corporation
Inga Ortseifer: Biopharmaceutical New Technologies (BioNTech) Corporation
Isabel Vogler: Biopharmaceutical New Technologies (BioNTech) Corporation
Eva Godehardt: Biopharmaceutical New Technologies (BioNTech) Corporation
Sebastian Attig: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
Richard Rae: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
Andrea Breitkreuz: Biopharmaceutical New Technologies (BioNTech) Corporation
Claudia Tolliver: Biopharmaceutical New Technologies (BioNTech) Corporation
Martin Suchan: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
Goran Martic: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
Alexander Hohberger: University Medical Center of the Johannes Gutenberg University
Patrick Sorn: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
Jan Diekmann: Biopharmaceutical New Technologies (BioNTech) Corporation
Janko Ciesla: EUFETS GmbH
Olga Waksmann: EUFETS GmbH
Alexandra-Kemmer Brück: Biopharmaceutical New Technologies (BioNTech) Corporation
Meike Witt: Biopharmaceutical New Technologies (BioNTech) Corporation
Martina Zillgen: Biopharmaceutical New Technologies (BioNTech) Corporation
Andree Rothermel: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
Barbara Kasemann: TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH
David Langer: Biopharmaceutical New Technologies (BioNTech) Corporation
Stefanie Bolte: Biopharmaceutical New Technologies (BioNTech) Corporation
Mustafa Diken: Biopharmaceutical New Technologies (BioNTech) Corporation
Sebastian Kreiter: Biopharmaceutical New Technologies (BioNTech) Corporation
Romina Nemecek: Medical University of Vienna
Christoffer Gebhardt: German Cancer Research Center (DKFZ)
Stephan Grabbe: University Medical Center of the Johannes Gutenberg University
Christoph Höller: Medical University of Vienna
Jochen Utikal: German Cancer Research Center (DKFZ)
Christoph Huber: Biopharmaceutical New Technologies (BioNTech) Corporation
Carmen Loquai: University Medical Center of the Johannes Gutenberg University
Özlem Türeci: CI3 - Cluster for Individualized Immunointervention e.V

Nature, 2017, vol. 547, issue 7662, 222-226

Abstract: The authors report the first-in-human application of personalized neo-antigen RNA vaccines in patients with melanoma.

Date: 2017
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://www.nature.com/articles/nature23003 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:547:y:2017:i:7662:d:10.1038_nature23003

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature23003

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().